NewsBenzingaSOPHiA GENETICSとMyriad Genetics、新たな前立腺がん特異的ゲノム不安定性スコア技術の進展に向けて提携 SOPHiA GENETICSとMyriad Genetics、新たな前立腺がん特異的ゲノム不安定性スコア技術の進展に向けて提携 Benzinga 2026.10.08 13:03 (GMT+0) Open on Benzinga Other news Morgan Stanley Maintains Underweight on Lazard, Lowers Price Target to $41 Wells Fargo Maintains Overweight on BlackRock, Lowers Price Target to $1230 RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $345 Wells Fargo Maintains Equal-Weight on Levi Strauss, Lowers Price Target to $20 Jeff Bezos Could Take Blue Origin Public. Amazon Investors Just Got a New Space Question Morgan Stanley Maintains Overweight on Houlihan Lokey, Lowers Price Target to $165
